Psoriasis

Zerigo Health announced the launch of Zerigo 2.0 ecosystem, a digital platform that connects health care systems and patients to the management and phototherapy treatment of chronic skin conditions, according to a company press release.

In this Healio exclusive video, Jashin J. Wu, MD, FAAD, of the University of Miami Miller School of Medicine, discusses his American Academy of Dermatology Annual Meeting presentation on biologics and biosimilars in psoriasis treatment.

In this Healio video exclusive, Jashin J. Wu, MD, FAAD, of the University of Miami Miller School of Medicine, discusses a study following the use of oral roflumilast to treat plaque psoriasis.

In this Healio video exclusive, Jashin J. Wu, MD, FAAD, covers a presentation from the American Academy of Dermatology Annual Meeting on a study of orismilast, a novel phosphodiesterase-4 inhibitor, in the treatment of psoriasis.

In this Healio video exclusive, Jashin J. Wu, MD, FAAD, discusses DICE Therapeutics’ phase 1 study of DC-806, a new oral interleukin-17A inhibitor, as an alternative to injectable medications in psoriasis treatment.

In this Healio video exclusive, Jashin J. Wu, MD, FAAD, covers a presentation from the American Academy of Dermatology Annual Meeting on TAK-279, a tyrosine kinase 2 inhibitor, in the treatment of individuals with severe psoriasis.

In this Healio video exclusive, Jashin J. Wu, MD, FAAD, discusses the benefits of switching patients with psoriasis to risankizumab after suboptimal response from secukinumab or ixekizumab treatment.

Psoriasis patients taking methotrexate are nearly three times as likely to develop nonmelanoma skin cancer compared with those not taking the drug, according to a study.

While topical formulas continue to be a primary treatment option in psoriasis, patients have reported certain characteristics that impact their adherence and willingness to use these medications, according to a study.

Almirall announced the publication of the first dermatological clinical study protocol to assess patient well-being as a primary endpoint in the treatment of moderate to severe plaque psoriasis, according to a company press release.